title: Hydrofluoroalkane-beclomethasone dipropionate effectively improves airway eosinophilic inflammation including the distal airways of patients with mild to moderate persistent asthma as compared with fluticasone propionate in a randomized open double-cross study.
abstract: BACKGROUND
  To evaluate whether hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) controls eosinophilic inflammation, including that in the distal airways, more effectively than fluticasone propionate (FP) Diskus.
  
  
  METHODS
  Fifty patients with well-controlled mild to moderate persistent asthma using FP for more than 6 months were randomly assigned to FP and HFA-BDP groups, and the treatment regimens of the two groups were switched twice between FP and HFA-BDP in a double cross-over manner at 3-month intervals after 2-week washout periods. Evidence of eosinophilic inflammation in blood and induced sputum samples was assessed, together with pulmonary function testing and an Asthma-related Quality of Life Questionnaire (AQLQ) survey after each treatment period.
  
  
  RESULTS
  The peripheral blood differential eosinophil count and sputum levels of eosinophil cationic protein (ECP) showed reciprocal changes during the study periods in both groups. The blood differential eosinophil count was significantly lower during the HFA-BDP than during the FP treatment period in both the FP (p = 0.004) and the HFA-BDP (p = 0.020) group. The late-phase induced sputum ECP level was significantly decreased during the HFA-BDP treatment period in both the FP (p = 0.016) and the HFA-BDP group (p = 0.023). The significant elevation of surfactant protein D values in the late-phase sputum observed in both groups indicated that late-phase sputum was obtained mainly from proximal peripheral airways. Both symptom and activity limitation domains of the AQLQ in the HFA-BDP group significantly increased after switching from FP to HFA-BDP. There were no significant changes in pulmonary function indices in either group at any time during the study.
  
  
  CONCLUSIONS
  HFA-BDP improved residual eosinophilic inflammation in asthmatic airways, including distal airways, more effectively than FP.
authors.affiliation: Department of Allergy and Respiratory Medicine, Tohno-Kousei Hospital, Gifu, Japan. ohbayasi@nn.iij4u.or.jp
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ohbayashi
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Adachi
mesh_terms: D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D001507:Beclomethasone / Q000627:therapeutic use*; D018592:Cross-Over Studies; D047150:Eosinophil Cationic Protein / Q000032:analysis; D004802:Eosinophilia / Q000150:complications / Q000188:drug therapy*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D013183:Sputum
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D000068298:Fluticasone; D047150:Eosinophil Cationic Protein; D001507:Beclomethasone